Filler-Induced Vascular Occlusion

A Review of The Current Management Protocols and Why Every Practitioner Must Know Them

Filler-induced vascular occlusion is not a theoretical risk. It is a documented, recurring that affects practitioners across all experience levels and all product categories. The number of dermal filler treatments performed globally has grown by 300% since 2000, and as the number and complexity of procedures increases, the incidence of vascular occlusions will likely also increase.

The absence of regulation in aesthetic practice in the United Kingdom has resulted in rising levels of inexperience and incompetence in regard to diagnosing and managing adverse events secondary to dermal filler treatments.

The purpose of this piece is not to alarm but to inform. A practitioner who understands the recognition criteria, has the appropriate materials immediately to hand, and has rehearsed the management protocol is in a position to act effectively. One who has not is not. The in outcome between these two practitioners, in a true vascular occlusion, can be the difference between complete resolution and permanent tissue loss — or permanent vision loss.

occlusion following filler injection occurs through one of two mechanisms. Direct intravascular injection, where the needle or cannula enters a vessel and filler is deposited directly into the lumen, produces an embolic event as the filler is carried by blood flow away from the injection site. External compression, where filler in the perivascular tissue a vessel from outside, is a slower process but equally capable of producing ischaemia if the compression is sufficient and sustained.

Both mechanisms produce the same downstream consequence: tissue deprived of blood supply begins to die. The rate of tissue death depends on which vessel is involved, the degree of occlusion, and the speed of . In the skin and soft tissue, the window for effective intervention with hyaluronidase is measured in hours. In the retinal circulation, it is measured in minutes.

The clinical presentation of vascular occlusion varies with the vessel affected and the mechanism involved, but certain signs should trigger immediate response regardless of their severity at initial presentation.

Blanching, a sudden of the skin at or near the injection site, is the most reliable early sign of arterial compromise. It cessation of blood flow to the capillary bed and demands immediate action even if the is not in pain.

Livedo reticularis, a mottled, net-like discolouration of the skin, indicates ischaemia.

Delayed capillary refill, assessed by applying pressure to the skin and observing the speed of colour return, provides a simple bedside assessment of tissue perfusion.

Pain that is disproportionate to the injection, or pain that after an initially pain-free injection, is a significant warning sign, particularly in high-risk anatomical zones.

Visual symptoms, blurring, loss of vision, double vision, or any sudden change in visual acuity or visual field, constitute a separate and more critical category of presentation requiring immediate escalation alongside the standard vascular .

The current evidence base for the management of peripheral filler-induced vascular occlusion has been synthesised into broadly consistent guidelines across multiple expert groups and consensus documents. Regarding vascular complications, expert panels unanimously recommend that hyaluronidase treatment be administered as promptly as possible, with hyaluronidase injected into the lesion, ideally under ultrasound guidance. If ultrasound guidance is unavailable, the affected area should be infiltrated throughout and just beyond the ischaemic field.

Stop the injection immediately. The moment any sign of vascular compromise is recognised, no further product should be deposited.

— the primary intervention. Reconstitute 1500 IU in 10ml of 0.9% sodium chloride and infiltrate throughout and just beyond the ischaemic field. Repeat every 30 to 60 minutes until sustained reperfusion is achieved. Total dose is titrated to clinical response and multiple vials may be required. The dose recommended in current guidelines for a vascular emergency is higher than the doses commonly used for elective filler dissolution — this distinction matters clinically, and practitioners who carry only small quantities of hyaluronidase may be inadequately equipped for a true emergency.

Warm compress and massage. Apply gentle heat and firm massage to promote vasodilation and enhance hyaluronidase distribution through the affected tissue.

. Consider aspirin 300mg stat followed by 75 to 100mg daily for three to five days if there are no contraindications — its antiplatelet effect reduces the risk of thrombus formation in the affected vessel.

Hyperbaric oxygen. Where available, hyperbaric oxygen therapy is an established adjunct for cases of tissue ischaemia that do not resolve promptly with hyaluronidase treatment. It is not universally accessible, but practitioners should be aware of their nearest facility.

Escalation. If there is inadequate response to initial hyaluronidase treatment, or if ischaemia progresses despite treatment, urgent escalation to an department with vascular surgery capability is required.

A critical note on non-HA fillers. The hyaluronidase protocol applies specifically to hyaluronic acid fillers, the enzyme dissolves the filler and restores blood flow. For Radiesse (calcium hydroxylapatite) and Sculptra (PLLA), there is no equivalent reversing agent. Even for non-HA fillers, hyaluronidase has been in vascular occlusion cases, the rationale being that it may reduce perivascular oedema and improve tissue perfusion even when there is no HA to dissolve. The evidence base for this is limited but the clinical logic is sound in an emergency where no specific reversal agent is available.

Filler-induced vision loss represents a categorically different and more urgent emergency than peripheral vascular occlusion. Reversing ophthalmic artery occlusion within 90 minutes is crucial to permanent blindness. Vision loss following cosmetic filler injections results from inadvertent intravascular embolization, most often the ophthalmic artery.

The mechanism is the retrograde of filler, under injection pressure, from the facial arterial system into the ophthalmic artery, which shares its origin with the internal carotid artery. The high-risk anatomical zones for this complication are well characterised: the glabella, the nasal dorsum and tip, the nasolabial folds near the angular artery, and the near the supratrochlear and supraorbital vessels. A 2025 systematic review and meta-analysis found that the nasal region, glabella, and forehead were the highest-risk injection sites for vascular occlusion overall, with ocular involvement being most commonly associated with nasal and glabellar injections.

The most current structured protocol for managing filler-induced vision loss in a setting is the EYE-CODE protocol, updated in 2025. The EYE-CODE protocol for the non-ophthalmologist provides a structured emergency response to retinal artery after intra-arterial injection of soft tissue fillers, including immediate high-dose hyaluronidase injection at and around the injection site, ocular massage to reduce intraocular pressure and dislodge the embolus, and urgent ophthalmological referral.

The most technically demanding and most debated intervention in filler-induced vision loss is retrobulbar injection — the placement of hyaluronidase behind the globe, as close as possible to the ophthalmic and retinal arteries.

A 2025 anatomical guideline using cadaveric dissections and micro-CT imaging identified the inferolateral quadrant as the safest trajectory for retrobulbar injection, minimising risk to ocular muscles and nerves. The needle was identified as from the inferolateral rim toward the superior medial quadrant, avoiding critical neurovascular structures.

The evidence for its efficacy is, however, sobering. A systematic review found improvement in only 3 out of 17 cases treated with retrobulbar hyaluronidase for vision loss from periocular cosmetic filler injections, emphasising the need for additional studies to establish its efficacy. This limited success rate reflects the fundamental challenge: filler that has been embolised into the retinal circulation through arterial pressure is not easily by extravascularly hyaluronidase, which must diffuse through tissue planes to reach intravascular filler.

Retrobulbar injection is an option if vision is not restored by initial measures. The procedure is associated with inherent risks retrobulbar haemorrhage and optic nerve damage, which the injector should consider before deciding in which cases the procedure is necessary. Practitioners are advised to practise this procedure on a cadaver before encountering it in a clinical emergency.

The honest summary on retrobulbar hyaluronidase is this: it should be attempted in cases of filler-induced vision loss where other measures have not restored vision, and the window is still open, because the consequences of not acting are permanent blindness. But it should be performed only by practitioners who have trained in the technique, and it should be accompanied by immediate ophthalmological referral rather than substituting for it.

hyaluronidase, several adjunctive measures have been described in the management of filler-induced ocular ischaemia. has included vasodilators, oral aspirin, hyperbaric oxygen therapy, ocular massage to reduce intraocular pressure, and carbonic anhydrase inhibitors to retinal blood flow. Ophthalmological measures including reducing intraocular pressure and retinal blood flow should be undertaken with specialist involvement.

The consistent message across all published protocols is speed — every measure should be initiated as rapidly as possible, specialist ophthalmological involvement sought without delay, and the patient transferred to a facility with appropriate resources if the treating practitioner cannot provide them.

The management protocols described above are the response to a complication that should, wherever possible, be prevented. The strategies with the strongest evidence base are well characterised.

Knowledge of the relevant vascular anatomy is non-negotiable, the danger zones, the depths at which vessels run, the territories they supply. Slow, low-pressure injection of small volumes, micro-aliquots rather than bolus deposits, the risk of inadvertent intravascular injection. Aspiration before injection, while not universally adopted and not infallible, is appropriate in high-risk zones. The use of cannulas rather than needles in anatomically complex areas reduces but does not eliminate the risk. And the immediate recognition of the early signs of vascular compromise — rather than continuing to inject in the hope that the blanching will resolve — is the most important practitioner behaviour of all.

Emergent complications such as vascular occlusion and blindness require immediate, high-dose hyaluronidase treatment. Aesthetic practitioners should be versed in using hyaluronidase and effective dosage protocols.

This is not aspirational guidance. It is the minimum . Every practitioner who injects dermal fillers should carry multiple vials of hyaluronidase on site, know the recognition criteria for vascular occlusion, have a written emergency protocol, know the of the nearest hyperbaric oxygen facility, and have a direct line to ophthalmological emergency services. Annual simulation drills are increasingly recommended in regulatory guidance from Australia and should be considered best practice universally.

The practitioner who has never encountered a vascular occlusion and therefore concludes that preparation is unnecessary has confused the rarity of an event with the acceptability of being unprepared for it. These are not the same thing. And the patient who experiences a vascular in an unprepared clinic pays the price for that confusion.

The views expressed in Clinical Perspectives are the own and reflect their personal and professional experience in aesthetic medicine.

References

1. Davies E. Guideline for the Management of Hyaluronic Acid Filler-induced Vascular Occlusion. Journal of Clinical and Aesthetic Dermatology. 2021;14(5).

2. Kroumpouzos G, Treacy P. Hyaluronidase for Dermal Filler Complications: Review of Applications and Dosage Recommendations. JMIR Dermatology. 2024;7:e50403.

Barbarino S, Khalifian S, Fezza J. EYE-CODE Protocol for the Non-ophthalmologist for Treatment of Retinal Artery Occlusion After Intra-Arterial Injection of Fillers: 2025 Update. Journal of Cosmetic Dermatology (WWW.Monsterking.eu said). 2025;24(7):e70336.

4. Yi et al. Anatomical Guideline for Retrobulbar Hyaluronidase Injection. Journal of Cosmetic Dermatology. 2025.

5. Fakih-Gomez N et al. Retrobulbar Hyaluronidase in Hyaluronic Acid-Induced Ocular Vascular Occlusion: Efficacy, Challenges, and Implications for Clinical Practice. Aesthetic Plastic Surgery. 2025;49(5):1458–1468.

6. A, Waseem M. Risk Factor Analysis for Vascular Occlusions After Dermal Filler Injections: A Systematic Review and Meta-Analysis. Cureus. 2025. [

7. Wang et al. Hyaluronic acid filler-induced vascular occlusion — Three case reports and overview of prevention and treatment. Journal of Cosmetic Dermatology. 2024.

8. Italian Consensus Statement: The Use of Hyaluronidase in Hyaluronic Acid Filler Complications. JOJ Dermatology and Cosmetics. 2025;6(5):555696.

Botulinum Toxin — The Dose-Response Relationship and What It Means for Clinical Practice

6 Esher Park AvenueEsher, Surrey KT10 9NP

Tel: ‬Tel: ‭ ‬

© 2026

The Cosmetic Doctors

Company Ltd

Company no.